Background Experience in the use of apremilast in clinical practice complements the
information available from pivotal clinical trials. Materials and methods Following a review of …

Objectives The aim of this paper is to present our personal as well as literature-sourced real-
world evidenced on apremilast use in psoriasis patients with serious baseline comorbidities …

Introduction: Psoriasis is a chronic inflammatory skin disease characterized by dysregulation
of the immune system and release of pro-inflammatory mediators. Drugs available for …

Background Little has been published on the real‐world effectiveness and safety of
apremilast in psoriasis. Objectives To evaluate the effectiveness, safety and drug survival of …

Apremilast has been approved as an effective and safe treatment for psoriasis, but clinical
trial results may differ from real‐life data. This retrospective cross‐sectional study evaluated …

Background: Apremilast is an oral phosphodiesterase 4 (PDE4) inhibitor used for the
treatment of moderate to severe psoriasis. Long-term data on the effectiveness and drug …

Background The evidence for adding small-molecule drugs to an ongoing biologic treatment
is sparse, but combination therapies appear to be advantageous in appropriately selected …

Introduction L'apremilast complète l'arsenal thérapeutique du psoriasis depuis octobre
2016. Les données des études cliniques sont rassurantes en termes de tolérance mais on …

Background and objectives It is necessary to expand the knowledge in the use of apremilast
in clinical practice. The APPRECIATE study (NCT02740218) aims to describe the …

Introduction: Psoriasis is a common skin disorder characterized by chronic inflammatory
lesions that are frequently vexing for patients and difficult for physicians to treat. Although …